<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856774</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-II-207</org_study_id>
    <nct_id>NCT04856774</nct_id>
  </id_info>
  <brief_title>Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to assess the safety, tolerability, and efficacy when&#xD;
      combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted&#xD;
      in 2 phases, Phase Ib and Phase II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recommended phase 2 dose (Phase Ib)</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity (DLT) (Phase 1b)</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events (TEAEs)</measure>
    <time_frame>For each participant, from the first dose till 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent serious adverse events (SAEs)</measure>
    <time_frame>For each participant, from the first dose till 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response(TTR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">113</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>SHR -1701 + BP102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701ï¼›BP102</intervention_name>
    <description>Drug: SHR-1701 IV infusion&#xD;
Drug: BP102 IV infusion&#xD;
Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined.</description>
    <arm_group_label>SHR -1701 + BP102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed solid malignancy that is metastatic or&#xD;
             unresectable for which standard curative or palliative measures do not exist or are no&#xD;
             longer effective (phase Ib)&#xD;
&#xD;
          2. Histologically or cytologically confirmed metastatic or locally advanced solid tumors&#xD;
             of the selected indications. (Phase II).&#xD;
&#xD;
          3. .Life expectancy exceeds 12 weeeks;&#xD;
&#xD;
          4. The Eastern Cancer Cooperative Group (ECOG) has a performance score of 0 or 1;&#xD;
&#xD;
          5. Normal organ and marrow function;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has known active central nervous system (CNS) metastases. Subjects with previously&#xD;
             treated brain metastases may participate provided they are stable.&#xD;
&#xD;
          2. A history of human immunodeficiency virus (HIV) infection is known, or has an active&#xD;
             autoimmune disease.&#xD;
&#xD;
          3. History of interstitial lung disease or pneumonia requiring oral or intravenous&#xD;
             steroids.&#xD;
&#xD;
          4. Has moderate or severe cardiovascular disease;&#xD;
&#xD;
          5. Active HBV(hepatitis B) or HCV (Hepatitis C virus)-infected subjects;&#xD;
&#xD;
          6. Any other malignancies within 5 years except for those with negligible risk of&#xD;
             metastasis or death.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hao Shen</last_name>
    <phone>+0518-82342973</phone>
    <email>hao.shen@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiyuan Pan</last_name>
    <phone>15258682523</phone>
    <email>yiyuan.pan@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Doctor</last_name>
      <phone>+86-20-87343468</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

